Bolt Biotherapeutics (BOLT) Competitors $5.74 0.00 (0.00%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$5.70 -0.04 (-0.78%) As of 07/17/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT vs. CRIS, SABS, MTEM, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and UTHRShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Curis (CRIS), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Its Competitors Curis SAB Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Bolt Biotherapeutics (NASDAQ:BOLT) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk. Does the media refer more to BOLT or CRIS? In the previous week, Bolt Biotherapeutics had 1 more articles in the media than Curis. MarketBeat recorded 1 mentions for Bolt Biotherapeutics and 0 mentions for Curis. Bolt Biotherapeutics' average media sentiment score of 1.94 beat Curis' score of 1.87 indicating that Bolt Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Bolt Biotherapeutics Very Positive Curis Very Positive Is BOLT or CRIS more profitable? Bolt Biotherapeutics has a net margin of 0.00% compared to Curis' net margin of -376.08%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt BiotherapeuticsN/A -94.51% -59.07% Curis -376.08%N/A -97.14% Do insiders and institutionals believe in BOLT or CRIS? 86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 6.1% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 5.5% of Curis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher valuation & earnings, BOLT or CRIS? Curis has higher revenue and earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$7.69M1.43-$63.12M-$33.40-0.17Curis$10.91M1.76-$43.39M-$6.23-0.30 Which has more risk & volatility, BOLT or CRIS? Bolt Biotherapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.6, indicating that its stock price is 260% more volatile than the S&P 500. Do analysts rate BOLT or CRIS? Bolt Biotherapeutics currently has a consensus target price of $50.00, indicating a potential upside of 771.08%. Curis has a consensus target price of $17.00, indicating a potential upside of 823.91%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Bolt Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCuris beats Bolt Biotherapeutics on 8 of the 15 factors compared between the two stocks. Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11M$2.94B$5.57B$9.34BDividend YieldN/A2.45%3.80%4.06%P/E Ratio-0.1720.2928.1019.86Price / Sales1.43302.32441.4199.96Price / CashN/A43.1635.8457.94Price / Book0.197.838.265.67Net Income-$63.12M-$55.11M$3.24B$257.80M7 Day Performance-7.27%3.21%1.48%1.87%1 Month Performance1.41%12.86%8.07%10.92%1 Year Performance-61.22%5.06%30.29%18.51% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics2.7345 of 5 stars$5.74flat$50.00+771.1%-61.2%$11M$7.69M-0.1790News CoveragePositive NewsCRISCuris2.597 of 5 stars$1.74-3.9%$17.00+877.0%-72.2%$18.94M$10.91M-0.2860Positive NewsHigh Trading VolumeSABSSAB Biotherapeutics3.3423 of 5 stars$1.96+14.0%$13.25+576.0%-2.7%$15.98M$1.32M-0.53140Gap UpMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.4181 of 5 stars$292.95-1.8%$307.82+5.1%-11.1%$160.37B$33.42B26.7328,000Trending NewsAnalyst RevisionGILDGilead Sciences4.8997 of 5 stars$111.78+0.0%$110.55-1.1%+48.4%$139.01B$28.75B23.5317,600Trending NewsInsider TradeAnalyst RevisionVRTXVertex Pharmaceuticals4.7365 of 5 stars$459.410.0%$511.62+11.4%-5.1%$118.03B$11.02B-117.206,100Trending NewsAnalyst ForecastAnalyst RevisionREGNRegeneron Pharmaceuticals4.7814 of 5 stars$538.11-1.7%$813.57+51.2%-49.3%$59.10B$14.09B13.7015,106ALNYAlnylam Pharmaceuticals4.0404 of 5 stars$324.13-2.3%$341.91+5.5%+35.3%$43.28B$2.25B-155.092,230Trending NewsAnalyst ForecastAnalyst RevisionBIIBBiogen4.9064 of 5 stars$130.13-2.1%$188.48+44.8%-43.6%$19.47B$9.68B12.857,605Trending NewsInsider TradeAnalyst RevisionUTHRUnited Therapeutics4.9835 of 5 stars$290.39-1.4%$386.15+33.0%-10.3%$13.28B$2.88B11.591,305Positive News Related Companies and Tools Related Companies Curis Alternatives SAB Biotherapeutics Alternatives Molecular Templates Alternatives Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
